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Abstract
Background: The epidermal growth factor receptor (EGFR) is a validated therapeutic target in non-small cell lung
cancer (NSCLC). However, current single agent receptor targeting does not achieve a maximal therapeutic effect,
and some mutations confer resistance to current available agents. In the current study we have examined, in
different NSCLC cell lines, the combined effect of RNA interference targeting the EGFR mRNA, and inactivation of
EGFR signaling using different receptor tyrosine kinase inhibitors (TKIs) or a monoclonal antibody cetuximab.
Methods: NSCLC cells (cell lines HCC827, H292, H358, H1650, and H1975) were transfected with EGFR siRNA and/or
treated with the TKIs gefitinib, erlotinib, and afatinib, and/or with the monoclonal antibody cetuximab. The
reduction of EGFR mRNA expression was measured by real-time quantitative RT-PCR. The down-regulation of EGFR
protein expression was measured by western blot, and the proliferation, viability, caspase3/7 activity, and apoptotic
morphology were monitored by spectrophotometry, fluorimetry, and fluorescence microscopy. The combined
effect of EGFR siRNA and different drugs was evaluated using a combination index.
Results: EGFR-specific siRNA strongly inhibited EGFR protein expression almost equally in all cell lines and inhibited
cell growth and induced cell apoptosis in all NSCLC cell lines studied, albeit with a different magnitude. The effects
on growth obtained with siRNA was strikingly different from the effects obtained with TKIs. The effects of siRNA
probably correlate with the overall oncogenic significance of the receptor, which is only partly inhibited by the
TKIs. The cells which showed weak response to TKIs, such as the H1975 cell line containing the T790M resistance
mutation, were found to be responsive to siRNA knockdown of EGFR, as were cell lines with downstream TKI
resistance mutations. The cell line HCC827, harboring an exon 19 deletion mutation, was more than 10-fold more
sensitive to TKI proliferation inhibition and apoptosis induction than any of the other cell lines. Cetuximab alone
had no relevant in vitro activity at concentrations obtainable in the clinic. The addition of EGFR siRNA to either TKIs
or cetuximab additively enhanced growth inhibition and induction of apoptosis in all five cell lines, independent of
the EGFR mutation status (wild-type or sensitizing mutation or resistant mutation). The strongest biological effect
was observed when afatinib was combined with an EGFR-specific siRNA.
Conclusions: EGFR knockdown by siRNA further decreases the cell growth of lung cancer cells that are treated
with TKIs or cetuximab alone, confirming that single agent drug targeting does not achieve a maximal biological
effect. The siRNA inhibits EGFR oncogenic activity that bypasses downstream “resistance” mutations such as KRAS
and PTEN. The combined treatment of siRNA and EGFR inhibitory agents is additive. The combination of a potent,
irreversible kinase inhibitor such as afatinib, with EGFR-specific siRNAs should be further investigated as a new
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Background
Non-small cell lung cancer (NSCLC) comprises 75% to
85% of newly diagnosed lung cancers. Over 70% of
NSCLC patients present with advanced disease, and the
5-year survival rate for NSCLC is only 16%. For early-
stage or locally-advanced lung cancer, surgery is the
most effective treatment, and combined chemotherapy
is the standard adjuvant approach. For stage III/IV
NSCLC, platinum-based combined chemotherapy is the
current standard of care, but with much room for
improvement [1].
I nam i n o r i t yo fp a t i e n t s ,am u t a n te p i d e r m a lg r o w t h
factor receptor (EGFR) has become a validated thera-
peutic target and EGFR tyrosine kinase inhibitors (TKIs)
gefitinib and erlotinib are currently the first-line treat-
ment options for these patients [2,3]. These drugs lead
to impressive improvements in progression-free survival
(PFS) compared to chemotherapy. However, ultimately
these tumors develop resistance to these TKIs through
various mechanisms. A frequent mechanism is the
emergence of a malignant clone with a second mutation
in the EGFR kinase domain, a threonine-to-methionine
substitution at amino acid position 790 (T790M) [4].
The ErbB family includes four related receptor pro-
teins (EGFR/ErbB1/HER1, ErbB2/Neu/HER2, ErbB3/
HER3, and ErbB4/HER4). The ErbB family of membrane
receptors is a group of transmembrane glycoproteins
that consists of an extracellular ligand-binding domain,
a transmembrane domain, and an intracellular tyrosine
kinase domain mediating signal transduction. The com-
plex EGFR signal transduction pathway involves the
RAS/MAPK cascade, phosphatidyl inositol 3-kinase
(PI3K), signal transducer and activator of transcription
(STAT), and downstream protein kinase C (PKC). Fol-
lowing ligand binding, EGFR can homodimerize or het-
erodimerize with another member of the ErbB family,
causing activation of the intracellular tyrosine kinase
domain and receptor transphosphorylation. The newly
formed phosphotyrosine residues act as docking sites for
various adaptor molecules that consequently activate a
number of intracellular signaling cascades, that, in case
of constitutive activation of the pathway, leads to cell
proliferation, inhibition of apoptosis, angiogenesis, and
invasion/metastasis, resulting in tumor growth and pro-
gression [5].
Currently two main anti-EGFR strategies are in clini-
cal use: low-molecular-weight TKIs that compete with
ATP for binding to the tyrosine kinase portion of the
receptor, and monoclonal antibodies that are directed at
the ligand-binding extracellular domain thereby prevent-
ing ligand binding, receptor dimerization, and receptor
signaling. These two classes of agents have shown solid
preclinical and clinical activity in a variety of tumor
types [6].
Among the receptor TKIs, single-agent erlotinib (Tar-
ceva, Genentech, Inc, South San Francisco, CA, USA
and OSI Pharmaceuticals Inc., Melville, NY, USA)
improves survival in advanced NSCLC patients who pro-
gressed after chemotherapy [7-10] and is superior to
chemotherapy in the first-line treatment of lung adeno-
c a r c i n o m aw i t ha nE G F Rm u t a t i o ni ne x o n1 9 / 2 1[ 2 ] .
The aggregated clinical experience today indicates that
only patients whose tumors contain a sensitizing muta-
tion in the EGFR tyrosine kinase domain derive an
important and meaningful clinical benefit from these
agents. Some randomized studies indicate that in
patients not selected for such mutations these drugs
might even have an adverse effect on outcome [11]. In
an unselected patient population, gefitinib maintenance
therapy also failed to show a survival advantage [11].
Not all patients with tyrosine kinase domain muta-
tions respond to these inhibitors and even patients that
respond usually only achieve a partial remission. In
addition, some base-line mutations, for example those
located in exon 20 of the kinase domain, are resistant or
only weakly sensitive to current anti-EGFR TKIs. The
efficacy of the inhibitors is also limited in time due to,
in nearly half of the cases, the appearance of cells with a
second “resistance” mutation, usually T790M located in
the receptor tyrosine kinased o m a i n[ 4 ] .A na d d i t i o n a l
mechanism is the activation, either at baseline or
acquired, of c-Met over-expression. Afatinib (BIBW
2992, Boehringer Ingelheim GmbH), an irreversible dual
inhibitor of EGFR and HER2 kinases, retains some activ-
ity in tumors with T790M mutations although at doses
that are a log higher than what is needed for cancers
with only a sensitizing mutation [12]. Afatinib is cur-
rently being evaluated in phase III trials [13-17].
The chimerical IgG1 mAb cetuximab (ERBITUX,
ImClone Systems Incorporated, New York, NY, USA
and Bristol-Myers Squibb Company, Princeton, NJ,
USA) is the most comprehensively studied anti-EGFR
antibody. By blocking the ligand-receptor interaction,
cetuximab down-regulates EGFR signaling, thereby
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[6]. Cetuximab in combination with chemotherapy has
been approved by the FDA for the treatment of meta-
static colorectal cancer (CRC) and in combination with
radiotherapy or a platinum derivative for the treatment
of locally advanced head and neck cancer (HNC)
[18,19]. Cetuximab has modest activity as a single agent
as well as in combination with docetaxel in patients
with advanced, chemotherapy-refractory NSCLC [20]. A
multinational, multicentre, open-label, phase-III trial has
shown that addition of cetuximab to platinum-based
chemotherapy improved outcome for patients with
advanced NSCLC [21]. However, the effect is small and
no clear predictive biomarker has been identified.
The limitations of the clinical results obtained with
single agent EGFR TKIs or cetuximab justify the investi-
gation of additional therapeutic strategies, including
enhanced targeting of the EGFR. RNA interference
(RNAi), has been extensively explored in recent years in
many targets. The ability of small interference RNA
(siRNA) sequences to modulate gene expression has
provided a powerful tool with which to study gene func-
tion and is being explored in clinical trials [22,23]. How-
ever, the combined use of RNAi and other types of
EGFR targeting has not been explored.
In the current study we investigated whether the com-
bination of EGFR inhibitory agents with EGFR-specific
siRNA increases the therapeutic efficacy. To this end,
we have examined the effects of either treatment alone
versus the combination, in a set of lung cancer cell lines
differing in their genomic status.
Methods
Cell lines and reagents
The human NSCLC cell lines H292 (CRL-1848™,
mucoepidermoid pulmonary carcinoma) was kindly pro-
vided by Prof Dr Filip Lardon (Universiteit Antwerpen-
CDE Geneeskunde-Oncologie). H358 (CRL-5807™,
bronchoalveolar carcinoma), HCC827(CRL-2868™,a d e -
nocarcinoma), H1650(CRL-5883™, adenocarcinoma;
bronchoalveolar carcinoma), and H1975(CRL-5908™,
adenocarcinoma) were obtained from the American
Type Culture Collection (ATCC, Netherlands). The cell
line H292 was reported to be an EGFR and KRAS wild-
type cell line by others [24,25]. We confirmed the wild-
type status for both genes using real-time RT-qPCR and
sequencing analysis (data not shown). H358 is EGFR
wild-type and is mutated at codon 12 of KRAS [26], and
in addition has a homozygous deletion of p53 [27].
H1650 and HCC827 have an in-frame deletion in the
EGFR tyrosine kinase domain (EGFR tyrosine kinase
domainΔE746-A750, exon 19). H1650 cells have also a
deletion of the 3’ part of exon 8 and the entire exon 9
of PTEN, which causes loss of the protein [28] and in
addition express the insulin-like growth factor receptor
(IGF1R) [29]. The cell line H1975 has a sensitizing
L858R kinase domain mutation in exon 21, but also a
second mutation (T790M, in cis,i nt h ek i n a s ed o m a i n )
rendering them resistant to the reversible TKIs gefitinib
and erlotinib [30]. Moreover, these cells express the Met
receptor but without gene amplification [31]. Table 1
summarizes the relevant genomic status of the different
cell lines. All five cell lines were cultured in the same
RPMI 1640 medium (Invitrogen Corp., Gent, Belgium),
supplemented with 10% heat-inactivated fetal bovine
serum (Perbio Science NV, Erembodegem, Belgium), 2
mM L-glutamine and 1 mM sodium pyruvate at 37°C in
a humidified incubator with 5% CO2. TKIs gefitinib
(AstraZeneca, Cheshire, UK), erlotinib (AstraZeneca,
Cheshire, UK), and the EGFR+HER2 specific afatinib
(Boehringer Ingelheim, Ingelheim, Germany) stocks of
10 mM were prepared in dimethyl sulfoxide (DMSO)
a n ds t o r e da t- 8 0 ° C .T h eE G F R - s p e c i f i cm o n o c l o n a l
antibody cetuximab (2 mg/ml) was purchased from
Merck KgaA, Darmstadt, Germany and stored at 4°C.
The drugs were diluted in fresh RPMI 1640 with a final
concentration of DMSO less than 0.1% in all
experiments.
siRNA transfection
T h eE G F Rs p e c i f i cs i R N Ad e s i g n e db yI n v i t r o g e n( 5 ’
GCAAAGUGUGUAACGGAAUAGGUAU 3’)t a r g e t sa
sequence starting at nucleotide 1247 and lying at the
junction of exon 8 and 9 (ref. SKU#12938-076, Invitro-
gen Merelbeke, Belgium) [32]. The glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) positive control
siRNA (used in preliminary experiments to optimize the
siRNA transfection efficiency, data not shown) was also
from Invitrogen (ref. SKU#12935-140 Stealth RNAi
GAPDH Positive Control, Invitrogen Merelbeke, Bel-
gium). The negative control siRNA was from Eurogen-
tec (OR-0030-neg05, Eurogentec S.A., Liege, Belgium)
and consists of a proprietary siRNA sequence not corre-
sponding to any eukaryotic gene. Transfection was by
mixing siRNA with 1.5 μl Lipofectamine™2000 (Cat.
No. 11668-019, Invitrogen Merelbeke, Belgium) for a
final volume of 100 μl RPMI including 10% serum but
without antibiotics. The procedure was according to the
Table 1 Relevant genotypic changes in the NSCLC cell
lines studied
Cell lines EGFR status KRAS status PTEN
HCC827 Exon 19 deletion Wild-type +
H292 Wild-type Wild-type +
H358 Wild-type Mutant +
H1650 Exon 19 deletion Wild-type -
H1975 Exon 21 L858R + exon 20 T790M Wild-type +
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ciency was the “TOX” transfection control, a proprietary
RNA oligonucleotide that induces cell death, and siGLO
Green, a modified, fluorescent RNA duplex that loca-
lizes to the nucleus (ref. D-001630-01-02 and D-001500-
01-05, Thermo Scientific Dharmacon, Blenheim, UK).
RT-qPCR
RNA isolation, RNA normalization, and reverse transcrip-
tion were as described previously [32,33]. Intron-spanning
RT-PCR primers (synthesized by Eurogentec S.A., Liege,
Belgium) specific for EGFR or GAPDH mRNA were based
upon GenBank sequence (EGFR, GeneID: 1956,
NM_005228.3, and ENSEMBL sequence:
ENST00000275493; GAPDH, GeneID: 2597,
NM_002046.3, and Ensembl sequence:
ENSG00000111640). They were designed using the Roche
LightCycler Probe Design Software v1.0 followed by
BLAST analysis http://blast.ncbi.nlm.nih.gov/Blast.cgi. The
primer sequences were EGFR FWD: CGAGGGCAAATA-
CAGCTT, EGFR REV: AAATTCACCAATACCTATT,
and GAPDH FWD: TGAACGGGAAGCTCACTGG,
GAPDH REV TCCACCACCCTGTTGCTGTA. The
reverse primers were also used in the reverse transcription
step. Real-time qPCR was performed in the Roche Light-
Cycler
® 1.5 instrument with SYBR green detection and
melting curve analysis, as described previously [33]. The
target mRNA abundance in each sample was normalized
to its reference level as ΔCq = CqEGFR-CqGAPDH,w h e r e
the Cq value is the quantification cycle number. The value
ΔΔCq is the difference with a mock tranfected control.
Experiments were performed in triplicate. The reduction
of the EGFR mRNA level was expressed as a percentage
and calculated with the formula: (1-1/2
ΔΔCq) × 100 [32,34].
Western blot analysis
After being treated with siRNA for the indicated periods,
the cells were washed with PBS and lysed in a buffer con-
taining 80 mM Tris-HCl (ph 6.8), 5% SDS, 10% glycerol, 5
mM EDTA (ph 8), 5% 2-MercaptoEthanol, 0.2% Bromo-
phenolblue, and 1 mM phenylmethylsulfonyl fluoride. The
lysates were centrifuged at 12,000 × g for 10 min at 4°C
and boiled for 5 min. Twenty-five microgram protein of
each sample was subjected to SDS-PAGE (8% SDS-acryla-
mide gel) and the separated proteins were transferred to
hybond ECL nitrocellulose membranes (GE Healthcare
Bio-sciences/Amersham, Diegem, Belgium) for 2 h at 100
mA. The membrane was incubated with a non-phospho-
Tyr1173 EGFR antibody (1:1,000 dilution, clone 20G3,
mouse monoclonal IgG1К ,B i o - c o n n e c t ,H u i s s e n ,T h e
Netherlands.) or a b-actin antibody (ref. A1978 AC-15
1:2,000 dilution, Sigma-Aldrich N.V. Bornem, Belgium).
Primary antibodies were detected with an HRP-conjugated
secondary antibody (1:4,000 dilution, ECL Anti-mouse
IgG Peroxidse linked Na 931, GE Healthcare Bio-sciences/
Amersham, Diegem, Belgium) and finally the membranes
were subjected to chemiluminescence detection assay
(ECL Plus Western Blotting Detection Reagents, GE
Healthcare Bio-sciences/Amersham, Diegem, Belgium).
Experiments were repeated in triplicate.
Cell growth
Cell growth was assessed using a colorimetric tetrazolium
(MTS) assay (CellTiter96 AQueous One Solution Cell Pro-
liferation Assay G3580, Promega, Madison, WI, USA). The
protocol was as follows: siRNAs, gefitinib, erlotinib, afati-
nib, or cetuximab were added to 96 well plates at increas-
ing concentrations and incubated at 37°C for up to 72 h
(96 h for siRNA) for single treatments. For the siRNA/
TKI/antibody combinations, the agents were added to the
cells first, and 24 h later the cells were transfected with
EGFR siRNA in the same wells and incubated for another
48 h, because siRNA transfection efficiency is influenced
by the agents if performed at the same time. Following
addition of 20 μlo fM T Sr e a g e n tt oe a c hw e l l ,t h ep l a t e s
were incubated for 2 h at 37°C in a humidified 5% CO2
atmosphere, and the absorbance at 490 nm was recorded
using a 96-well microplate reader (Scientific Multiskan
MK3, Thermo Finland). All assays were performed in tri-
plicate. The results were the mean of six wells and
expressed as the ratio of the absorbance of siRNA and/or
agent treated wells/absorbance of mock control ×100.
Cell viability
To further confirm the data from the above MTS assay,
cell viability was detected by fluorimetric detection of
resorufin (CellTiter-Blue Cell Viability Assay, G8080,
Promega, Madison, WI, USA). The procedure was
according to the manufacturer. The treatments and con-
trols were as mentioned above. Fluorimetry (ex: 560
nm/em: 590 nm) was using an FL600 fluorescence plate
reader (Bio-Tek, Winooski, Vermont, USA). All assays
were performed in triplicate and each time six individual
wells were used. Fluorescence data are expressed as the
fluorescence of treated sample/mock control ×100.
Caspase-3/7 activity detection
Caspase-3/7 activity was measured using a synthetic rho-
damine labeled caspase-3/7 substrate (Apo-ONE
® Homo-
geneous Caspase-3/7 Assay, G7790, Promega, Madison,
WI, USA) performed immediately after the detection of
cell viability (described above) on the same wells, accord-
ing to the instructions of the manufacturer. After incuba-
tion at room temperature for 60 min, the fluorescence of
each well was measured (ex: 499 nm/em: 512 nm), using a
FL600 fluorescence plate reader (Bio-Tek, Winooski, Ver-
mont, USA). Caspase-3/7 activity is expressed as fluores-
cence of treated sample/mock control×100.
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morphology
The effects of EGFR siRNA and different agents on
apoptosis and nuclear morphology in the cells were
assessed by Hoechst 33342 (Sigma-Aldrich N.V. Bor-
nem, Belgium) and propidium iodide (PI, Sigma-Aldrich
N.V. Bornem, Belgium) double fluorescent chromatin
staining. In brief, after single or dual treatment of
siRNA and/or agents, cells were washed with ice-cold
P B Sa n ds t a i n e d1 5m i nw i t hH o e c h s t3 3 3 4 2( 1m g / m l )
and PI (1 mg/ml), and observed under an advanced
fluorescence microscope (ZEISS Axiovert 25, Zaventem,
Belgium). Apoptosis and nuclear morphology were iden-
tified by condensation of nuclear chromatin and its frag-
mentation. This system determines the absolute number
of viable cells (Hoechst 33342 positive/PI negative),
early apoptotic cells (Hoechst 33342 positive/PI negative
with blue fragmentations in the cells), late apoptotic
cells (Hoechst 33342 positive/PI positive, with red frag-
mentations in the cells), necrotic cells (PI positive), and
debris signals. Viable, apoptotic, and necrotic cells were
counted in 10 different fields under the 200 × vision in
each well in three independent experiments by two per-
sons and the average result was compared to the mock
control. Apoptotic cell numbers from different treat-
ments were compared by being normalized to their
viable cell numbers.
Statistical analysis
SPSS19.0 was used for statistical analysis. Results were
representative of three independent experiments unless
stated otherwise. Values were presented as the mean ±
standard deviation (SD). One-way Analysis of Variance
(ANOVA) test was used to analyze significance between
groups. The least significant difference (LSD) method of
multiple comparisons with parental and control group
was applied when the probability for ANOVA was sta-
tistically significant. Statistical significance was deter-
mined at a P < 0.05 level. In the analysis of additivity
and synergism, the theoretical zero-interaction (exactly
additive) dose-response curve for each siRNA + drug
combination was calculated by applying the Bliss inde-
pendence criterion [35,36]. Determination of possible
synergy was also assessed by the Biosoft CalcuSyn pro-
gram (Ferguson, MO, USA). The combination index
(CI) was used to express synergism (CI < 1), additive
effect (CI = 1), or antagonism (CI > 1) [37].
Results
Effects of EGFR-specific siRNA on target expression and
malignant phenotype
Among different EGFR-specific siRNAs that were
assessed for their ability to reduce EGFR mRNA levels,
an efficient 25 bp “validated stealth” oligonucleotide
from Invitrogen was chosen for its potent EGFR mRNA
knock-down efficiency [32,33]. Transcript levels were
detected by real-time RT-qPCR assay and relative quan-
tification using GAPDH gene transcript as a reference.
The knock-down ratios for the HCC827, H292, H358,
H1650, and H1975 cell lines were in the same range:
83%, 87%, 82%, 88%, and 94%, respectively. The expres-
sion level of the EGFR protein was verified by immuno-
blotting, 72 h post transfection (Figure 1). EGFR
expression in the cell lines transfected with EGFR-speci-
fic siRNAs was severely reduced compared to the nega-
tive control siRNA that had no effect. The EGFR-
specific siRNA thus significantly inhibits EGFR mRNA
and protein expression and with the same order of mag-
nitude in all cell lines studied, independent of the geno-
mic status of the EGFR.
A colorimetric MTS tetrazolium assay (CellTiter 96,
Promega, Madison, WI, USA) revealed that there was a
time-dependent reduction of 50% or more of cell growth
by the EGFR siRNA in all five cell lines. This was
achieved within a 72-h time frame, except for the
H1975 cell line carrying the T790M mutation that
needed 96 h to achieve the same degree of inhibition.
The steepest time response curve was in the H1650 cell
line carrying both an exon 19 activating mutation and a
PTEN mutation, and to a somewhat lesser degree in the
H358 cell line carrying a KRAS mutation. Within a time
frame of 72 h, a dose-dependent inhibition of cell
Figure 1 siRNA induced EGFR protein down-regulation.D o w n -
regulation of EGFR protein was detected by western blot 72 h post
transfection of 200 nM siRNAs.
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the H1650 cells were the most sensitive and H1975 cells
were the least sensitive cells (Figure 2A). To confirm the
results assessed by the MTS assay, the effect on viability
was assessed using a fluorimetric resorufin viability
assay (CellTiter Blue, Promega, Madison, WI, USA), and
by microscopic counting of viable (Hoechst 33342 posi-
tive/propidium iodide negative) cells. The results of
both assays largely mirrored the MTS tetrazolium assay
results (data not shown).
To verify whether the EGFR siRNA is able to induce
apoptosis, the CellTiter Blue assay was multiplexed with
a fluorescent caspase 3/7 assay. The results show a
time-dependent and dose-dependent caspase 3/7 signal
in all cell lines (Figure 3). The most sensitive cell lines
were the cell lines containing an exon 19 deletion
(HCC827 and H1650) and the H358 cell line containing
a KRAS mutation, while the H1975 and H292 cell lines
required a significantly longer exposure and higher
siRNA dose. In the H292 cell line even the highest con-
centration tested could not double the base line apopto-
tic level. A remarkable and unexpected high rate of
apoptosis induction was observed in the cell line H358.
The effect on apoptosis was confirmed microscopically
by Hoechst 33342 and PI double fluorescent staining
(data not shown). Again and surprisingly, in both assays
the highest apoptotic signals were recorded for the
H358 cell line, which is wild type for EGFR and carries
a KRAS mutation that activates signaling downstream of
EGFR (ERK/MAPK).
Targeting EGFR with kinase inhibitors alone
All the cells were treated with reversible EGFR TKIs
gefitinib and erlotinib, and the covalent inhibitor afatinib
(targeting both EGFR and HER2), and with the mono-
clonal EGFR antibody cetuximab. The effects were stu-
died in the colorimetric MTS tetrazolium proliferation
assay (Figure 4A). By far the most sensitive cell line was
HCC827, containing the exon 19 sensitizing mutation,
with IC50 values ≤ 0.1 nM for the three kinase inhibi-
tors. This was the case for the inhibition of cell growth
as well as the induction of apoptosis (Figures 4A, B).
The other cell lines lumped together and were 100- to
1,000-fold less sensitive to all three drugs, although
subtle differences in sensitivity were observed. Among
the three kinase inhibitors, afatinib had by far the high-
est molar potency in the sensitive HCC827 cell line,
which was especially striking for the induction of apop-
tosis. With afatinib, a doubling of the apoptotic rate was
already observed at the lowest concentration tested (10
nM). It is noteworthy that in H1975 cells carrying the
T790M resistance mutation, afatinib had a slightly
higher activity than the reversible kinase inhibitors, but
this difference was small and the activity was still loga-
rithmically inferior to what was observed in the
HCC827 cell lines. With cetuximab an effect could be
observed in all cell lines only in the supramicromolar
concentration range, which is higher than the serum
concentrations that are achieved at clinical dose levels,
and thus these cell lines are all considered to be rela-
tively resistant [38]. The effect of the TKIs and
Figure 2 Effect of EGFR siRNA transfection on the growth of the lung cancer cells. Both time-dependent and dose-dependent effects were
investigated. Cells were incubated in the presence of 200 nM siRNA for 0, 24, 48, 72, and 96 h (A) and also assessed with 0, 8, 40, or 200 nM
siRNA for 72 h (dose-response curves, B) using the MTS cell growth assay. Cell growth is expressed relative to the mock control group as
absorbance of siRNA/mock control ×100. The average ratio was calculated from six independent wells.
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Page 6 of 15Figure 3 Caspase 3/7 activity of the lung cancer cells with EGFR siRNA transfection. Effects of siRNA treatment on caspase-3/7 activity.
Cells were treated as mentioned in Figure 2, and the effect on caspase-3/7 activity was assayed and compared to the mock control in triplicate
at 0, 24, 48, 72, and 96 h post transfection (A). To accommodate the different cell numbers in the different treatments, caspase-3/7 induced
fluorescence was normalized to resorufin fluorescence (viability) from the same sample.
Figure 4 Effect of TKI treatment on cell growth inhibition and apoptosis induction. Effect of TKIs gefitinib, erlotinib, and afatinib and
cetuximab on the growth (A) and caspase3/7 activity (B) of HCC827, H292, H358, H1650, and H1975 cells after 72-h incubation. Independent
experiments were repeated six times and one representative result is shown. Points, mean value of six identical wells of a single representative
experiments; bars, SD (n = 6).
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ufin viability assay, yielding analogous results (data not
shown). Surprisingly, at relatively high concentration,
starting from one micro molar concentration and up,
erlotinib was able to induce caspase 3/7 signals in H358
cells (KRAS mutant, p53 minus) as high as in HCC827
cells.
The effect of adding an EGFR specific siRNA to either
EGFR TKIs or to cetuximab
The combination of siRNA with TKIs or cetuximab on
cell growth was also studied using the colorimetric MTS
formazan proliferation assay. The cells were first incu-
bated with the TKIs or cetuximab. To avoid interference
of these compounds with siRNA transfection, the trans-
fection was carried out 24 h later. There was an
enhancement of cell growth inhibition in all the five cell
lines treated with the siRNA - drug combinations com-
pared to either as a single agent alone. The most potent
combination was the EGFR-specific siRNA plus afatinib
(Figures 5, 6, 7, 8 and 9). As is observed in Figure 7,
addition of siRNA with the concentration of 200 nM
systematically further reduced cell growth in all cells
over afatinib alone. Likewise, by comparing also zero
afatinib dose with the samples treated with afatinib in
increasing doses it is also apparent that the addition of
afatinib to siRNA also increases the effect on growth.
To ascertain the additive or synergistic nature, a combi-
nation index was calculated [35,36]. The results unam-
biguously show that the combined inhibition of
proliferation is additive, since the combination indexes
a r ec l o s et oo re q u a lt oo n e( F i g u r e s5 B ,C ,D ,E ) .T h e
additive effect was the weakest in the cell line HCC827,
which is already the most sensitive to TKIs. This cell
line is 10-fold more sensitive for growth inhibition to
the combined action than the H292 and H358 cells and
100-fold more than the H1650 and H1975 cells. There
was also a potentiation of apoptosis in all the five cell
lines treated with the siRNA - drug combinations versus
either as a single agent alone (Figures 10 and 11). The
combined effect however is only clearly observed at
doses between 10 and 100 nM of afatinib in cell line
HCC827 and at supra micro molar doses of afatinib in
the other cell lines. Again, the effect of the combinations
of the drugs with siRNA was additive.
Discussion
The use of EGFR TKIs is a clinically validated therapeu-
tic option in NSCLC, especially for those tumors that
harbor a sensitizing EGFR kinase domain mutation.
However, single agent TKI treatment does not comple-
tely abrogate the oncogenic action of the receptor on
cell growth and apoptosis induction. Furthermore, initial
responders with mutant EGFR invariably develop sec-
ondary resistance to first generation TKIs [4,39,40]. Sev-
eral strategies are being investigated for improving this
therapeutic efficacy, by either combining EGFR TKI
with other agents aimed at inhibiting other growth fac-
tor pathways that are responsible for EGFR TKI resis-
tance, such as over-expressed c-Met. Another strategy is
to target the EGFR with other agents that can suppress
the oncogenic function, independent of the type of
Figure 5 Effect of adding an EGFR siRNA to gefitinib on cell growth inhibition. Lung cancer cells were treated with gefitinib 24 h before
the EGFR siRNA transfection. After transfecting the siRNA, the cells were incubated for another 48 h, after which cellular growth was assessed by
the MTS assay. (A) shows the combination effect of gefitinib and siRNA. *P < 0.05 and **P < 0.01 compared to controls with only siRNA
transfection. “black triangle” P < 0.05 and “double black triangles” P < 0.01 compared to agents plus control siRNA. Median-effect plot (B), dose-
effect curve (C), Fa-CI plot (D), and normalized isobologram (E) were computationally generated by Biosoft CalcuSyn program with EGFR siRNA
and combined to gefitinib in H358 cells. Similar additive effect was found in all the combinations in all the five cell lines (data not shown).
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Page 8 of 15mutation. An example is cetuximab. Recently, the addi-
tion of cetuximab to afatinib has yielded impressive
results in the treatment of EGFR reversible TKI resistant
lung cancer due to T790M mutation [41].
EGFR-specific siRNAs may be good candidates for
cancer therapy because of their specificity, efficiency,
and endurance in gene-specific silencing and ability to
suppress EGFR expression independent of the mutation
status of the gene. Currently, there are only a few
reports on the biological effects of EGFR siRNAs on
lung cancer cells [31,42-45]. Sordella et al. [44] used a
commercial EGFR wild-type siRNA pool that effectively
induced the apoptotic enzyme caspase 3 at 96 h post
transfection. The siRNA treatment also suppressed via-
bility in H1975 cells expressing a T790M mutant EGFR
and H1650 cells harboring a downstream PTEN muta-
tion, but not in H358 cells that are wild-type for EGFR.
In the present study, we have shown that an EGFR spe-
cific siRNA is very effective at suppressing the expres-
sion of EGFR in all cell lines tested, independent of the
EGFR mutation status. We have also shown that all cell
lines were variably inhibited in their growth by the
siRNA and that the siRNA induced apoptosis in a dose-
and time-dependent manner, upon transfection with
siRNAs targeting wild type EGFR. Our results are partly
in discordance with the data of Sordella et al. who,
albeit using different siRNA sequences (commercially
from Dharmacon, the concentration of siRNA was not
reported) and detecting assays, found no biological
effects in wild-type cells. These differences might reside
in the respective concentration of the siRNAs used and
the ability of the siRNAs to suppress gene expression
which was high and uniform across cell lines in our
experiments. Our results are in line with the report of
Rothenberg et al. [43], which showed that lentivirus-
based shRNA constructs targeting wild-type EGFR
mRNA could promote cell death. Furthermore, a reduc-
tion in cell viability was observed in EGFR wild-type
cells by Yamanaka et al. [45] who studied the effect of
an EGFR siRNA (5’-GUCAGCCUGAACAUAACAU-3’),
in different set of lung adenocarcinoma cell lines har-
boring a spectrum of EGFR wild-type, mutant, and
KRAS mutant cell lines (PC-9 [EGFR 15-bp exon 19
deletion]; H3255 [EGFR L858R]; HT-1 [wt EGFR and wt
KRAS]; 11-18 [wt EGFR and wt KRAS]; LK87 [KRAS
G12D]; A549 [KRAS G12S]).
Although all cell lines tested in the present study were
sensitive to our EGFR siRNA, some differences were
noted. First of all, the differential sensitivity towards
inhibition of cell growth versus apoptosis induction was
not the same. The effect of an siRNA upon important
aspects of the malignant phenotype, cell growth, and
s u r v i v a li sam e a s u r eo ft h es p e c i f i ca m p l i t u d eo ft h e
oncogenic potency and quality of the different
Figure 6 Effect of adding an EGFR siRNA to erlotinib on cell growth inhibition. Lung cancer cells were treated with erlotinib as mentioned
in Figure 5. *P < 0.05 and **P < 0.01 compared to controls with only siRNA transfection. “black triangle” P < 0.05 and “double black triangles” P
< 0.01 compared to agents plus control siRNA.
Figure 7 Effect of adding an EGFR siRNA to afatinib on cell growth inhibition. Lung cancer cells were treated with afatinib as mentioned
in Figure 5. *P < 0.05 and **P < 0.01 compared to controls with only siRNA transfection. “black triangle” P < 0.05 and “double black triangles” P
< 0.01 compared to agents plus control siRNA.
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Page 9 of 15mutations. The H1650 and HCC827 cell lines with an
exon 19 deletion were the most sensitive, both for
growth inhibition and apoptosis induction, confirming
t h a tt h ee x o n1 9m u t a t i o ni st h em o s to n c o g e n i ca n d
addictive. H1650 cells have been described as resistant
to TKIs due the loss of a functional PTEN suppressor
[28]. Our results indicate that the EGFR mutation in
H1650 cells at least partially bypasses the PTEN defi-
ciency in driving cell growth and survival and that such
a downstream mutation does not confer an absolute
resistance to EGFR inhibition. To the contrary, upon
siRNA treatment, this cell line was the second most sen-
sitive to both growth and apoptosis induction. The
lesser sensitivity of H1975 cells to EGFR siRNA treat-
ment despite an equally high inhibition of EGFR protein
expression indicates that the EGFR carrying a T790M
mutation in combination with an exon 21 mutation is a
less potent driver of cell growth and survival, which
could also help to explain the clinical resistance to TKI
inhibition of that receptor. Our siRNA results also con-
firm that in EGFR wild-type cells the receptor contri-
butes the least to the malignant phenotype if at all,
especially for cell survival. While there were anti-prolif-
erative effects in the H292 cell line with a wild-type sta-
tus, this cell line was relatively resistant to apoptosis
induction. This is in concordance with the clinical
experience that such cancers do not really benefit from
TKI treatment. The most puzzling of our results are in
the H358 cell line that has a wild-type EGFR receptor
and carries a homozygous KRAS mutation that normally
subverts the signaling emanating from the EGFR and
creates resistance to inhibition of the receptor with
TKIs or monoclonal antibodies [46,47]. In our experi-
ments this cell line was the most sensitive to apoptosis
induction and growth inhibition by siRNA EGFR inhibi-
tion. This result could not be explained by a higher
EGFR mRNA knockdown in this cell line. H358 cells
were found to be “KRAS-addicted” cells in which abla-
tion of KRAS expression by shRNA interference results
in apoptosis induction [48]. Inhibition of growth by
EGFR siRNA has also been observed in KRAS mutant
cell lines A549 and LK87 [45]. Our hypothesis is that
the strong reduction of EGFR induced by EGFR-specific
RNA interference, also induces a large depletion of
GRB2-SOS complexes necessary to load GTP into nor-
mal or mutant KRAS and hence interferes with KRAS
signaling. However, there are other, non-mutually exclu-
sive possibilities. H358 cells were found to secrete
increased levels of the EGFR ligand amphiregulin [49].
Knocking down EGFR expression would interrupt the
amphiregulin/EGFR positive feedback loop and this
could induce apoptosis. Thirdly, H358 cells were found
to have a high ErbB3 expression [50], and since EGFR
links to PI3K signaling via ErbB3, the PI3/AKT pathway
Figure 8 Effect of adding an EGFR siRNA to cetuximab on cell growth inhibition. Lung cancer cells were treated with cetuximab as
mentioned in Figure 5. *P < 0.05 and **P < 0.01 compared to controls with only siRNA transfection. “black triangle” P < 0.05 and “double black
triangles” P < 0.01 compared to agents plus control siRNA.
Figure 9 Effect of combination of EGFR siRNA and afatinib
with Hoechst 33342 and PI double fluorescent staining. Effect
of the combination of an EGFR siRNA and afatinib detected by
Hoechst 33342 and PI double fluorescent staining. The
concentrations were afatinib: 0.01 nM (assayed 72 h post treatment)
and EGFR siRNA: 200 nM (assayed 48 h post transfection). Similar
results were found with other concentrations of afatinib, and other
drugs in all the five cell lines (data not shown).
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Page 10 of 15may also be a major source of malignant growth in
these cells (in addition to KRAS). The removal of PI3K/
AKT signals by EGFR RNAi might then also lead to
apoptosis. Moreover, others have reported observations
that might point in the same direction as the present
study: Sunaga et al.[49] found that cell survival is not
much affected by KRAS knockdown in KRAS mutant
NSCLC cell lines and hypothesized that a feedback sig-
nal to EGFR and Akt leads to increased stimulation. An
additional mechanism for the observed effect might be
an off-target effect of erlotinib on the Janus kinase 2
(JAK2). Erlotinib was shown to decrease
phosphorylation of JAK2 and STAT-5 in EGFR-negative
myelodysplastic syndrome (MDS) cell lines KG-1 [50]
and erlotinib can disrupt signaling of the JAK2/STAT-5
pathway. JAK2 is activated by mutant p53 (or p53 defi-
ciency) [51]. Thus, some of the survival pathways ema-
nating from EGFR bypass KRAS in the cell line H358,
and the KRAS mutation is more important for resis-
tance to proliferation and less for apoptosis induction.
Our and others’ results suggest that the presence of a
KRAS mutation (or other unknown alterations in these
cells) could render H358 cells dependent on EGFR sig-
naling and that EGFR would be a candidate therapeutic
Figure 10 Enhancement of apoptosis induction by the combination of EGFR siRNA plus gefitinib or erlotinib. Lung cancer cells were
treated with different drugs 24 h before the EGFR siRNA transfection. Forty-eight hours post transfection, the cell cultures were assayed for
caspase-3/7 activity. (A: gefitinib; B: erlotinib). *P < 0.05 and **P < 0.01 compared to controls with siRNA transfection alone. “black triangle” P <
0.05 and “double black triangles” P < 0.01 compared to agents plus control siRNA.
Figure 11 Enhancement of apoptosis induction by the combination of EGFR siRNA plus afatinib or cetuximab. Experiments were
performed as mentioned in Figure 10. (A: afatinib; B: cetuximab). *P < 0.05 and **P < 0.01 compared to controls with siRNA transfection alone.
“black triangle” P < 0.05 and “double black triangles” P < 0.01 compared to agents plus control siRNA.
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explored the effects of a near maximal elimination of
EGFR using siRNA. Although our experiments do pro-
vide an estimate of the relative oncogenic potency of the
various EGFR mutations and downstream mutations,
currently we do not know whether it will be possible to
attain similar concentrations of a therapeutic equivalent
of our siRNA in vivo and in patients and thus obtain
similar efficacy.
It is within that window of a maximal effect of EGFR
inhibition that we have to analyze the results with TKI
or cetuximab inhibition, which are strikingly different.
The effect of TKI inhibition on the malignant phenotype
is indeed the integration of several variables: the onco-
genic potency of the targeted receptor, the significance
of the kinase activity to this oncogenic potency, the vari-
able sensitivity of the receptor to kinase inhibitors and
the relative potency of kinase inhibitors to shut down
this enzymatic activity. The action of monoclonal anti-
bodies is even more complex and more difficult to relate
to the mutational status of the receptor. By analogy to
what is observed in the clinical studies, the exon 19
deletion HCC827 cell line conferred by far the highest
sensitivity to TKI which is consistent with earlier reports
[4,29,39,42,52-55]. This is also consistent with the high
dependency of this cell line on this mutant receptor for
cell growth and survival in our siRNA experiments.
Comparatively, all other cell lines are to be considered
to be relatively resistant to TKI inhibition. The striking
difference with the siRNA results for the two cell lines
with downstream TKI resistance mutations (PTEN and
KRAS) indicates that the kinase activity of the receptor
is not the sole mediator of the oncogenic activity of
EGFR, although we observed some reflection of the
siRNA results in the KRAS mutant H358 cells, especially
with higher concentrations of erlotinib with regard to
apoptosis induction. None of the cell lines had a rele-
vant sensitivity to cetuximab alone under 10% FBS cul-
ture condition, and even the TKI sensitive cell line
HCC827 cells showed limited response. This might be
explained by the absence of an oncogenic significance of
the wild-type receptor and insensitivity of mutant recep-
tors to inhibition by monoclonal antibodies. Activating
mutations indeed confer hypersensitivity to TKIs, but
not necessarily to inhibition by monoclonal antibodies
[56]. The failure to detect a significant activity for cetux-
imab agrees with the absence of a significant activity as
single agent or very modest added benefit in clinical
lung cancer in association with chemotherapy [21].
Although EGFR is clearly a valid target in NSCLC
treatment, the efficacy demonstrated by EGFR-targeted
agents is not maximal as shown in preclinical models
and more recently in clinical trials [40,41]. One
approach to improve responsiveness to EGFR inhibitors
may be to simultaneously target multiple HER family
members. Afatinib is currently the most advanced com-
pound in this class. Afatinib is an irreversible EGFR/
HER2 inhibitor, with activity against wild-type and
mutant forms of EGFR [57]. Afatinib was more potent
than gefitinib, erlotinib, and lapatinib in inducing the
cell death of NSCLC cell lines, including those harbor-
ing wild-type EGFR, and the erlotinib-resistant T790M
mutation [57]. It was also found in the present study
(Figure 4) that the molar potency of afatinib against
these cells was significantly higher than either gefitinib
or erlotinib. HCC827 cells harboring the activating
E746_A750 deletion were highly sensitive to afatinib,
whereas other NSCLC cell lines were moderately sensi-
tive, which is in agreement with other reports [57,58].
The activity against the resistance mutation T790M and
cell lines with downstream resistance mechanisms was,
however, only slightly better than the reversible TKIs.
The several EGFR-targeting approaches differ in
action mechanisms. TKIs compete with ATP to bind to
the EGFR kinase, hence inhibiting EGFR autophosphor-
ylation and activation of downstream signaling. Anti-
EGFR antibodies prevent receptor dimerization and
hence activation [59]. However, none of these agents
alone does maximally suppress EGFR signaling or the
effect of mutant EGFR in the malignant phenotype, as
also shown in our experiments. The combination of
cetuximab with the different TKI has already been
tested [60,61]. The in vitro and in vivo results showed
that the combined treatment can augment the potency
of EGFR signaling inhibition. Ramalingam et al. [62]
used a combination of cetuximab and gefitinib for
patients with advanced/metastatic lung cancer who were
previously treated with platinum-based chemotherapy. It
was concluded that dual inhibition is feasible and safe,
and may have modest activity in advanced/metastatic
NSCLC. The combination of afatinib and cetuximab can
even overcome resistance due to the T790M mutation
both preclinically [40] as well as clinically [41]. In the
present study, the combined treatment of EGFR siRNA
and TKIs or antibody achieved increased tumor cell
growth suppression (about 30% more at the most) (Fig-
ures 5, 6, 7, 8, and 9) in all the five NSCLC cell lines
and increased apoptosis as high as by 100% (Figures 10
and 11). The effect with the different agents in the dif-
ferent cell lines was additive, not synergistic, as calcu-
lated by a combination index (CalcuSyn software).
Again, the differential sensitivity of the cell lines to the
combination mimicked their sensitivity to TKI alone:
the cell lines that demonstrated the most sensitivity to
siRNA had the largest effect from the combination,
including the cell lines with downstream TKI-resistance
mutations (which also in this context displayed the
highest sensitivity) or the T790M mutation. The least
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Page 12 of 15added effect was seen with afatinib associated to EGFR
siRNA in the cell line with the TKI sensitive exon 19
deletion mutation, in which afatinib alone is already
highly active at very low molar concentrations.
Conclusions
We conclude that RNA interference by siRNA oligonu-
cleotides should be further explored and developed as a
therapeutic modality in the treatment of EGFR mutant
lung cancer and also including KRAS mutant lung can-
cer, and lung cancers containing the resistance muta-
tions T790M or downstream pathway activation such as
PTEN inactivation. As already mentioned, it is not
known whether the concentration of siRNAs or an
equivalent of this used in the present study will be
achievable in vivo and in the clinic. EGFR siRNAs or a
similar technology that eliminates the receptor protein
physically from the cancer cell could help to improve
the treatment results in difficult to treat lung cancers.
Methods of in vivo siRNA delivery are currently being
researched, and some reports have already described the
systemic use of siRNA in cancer patients [63]. The most
appealing small molecule to test in a combination strat-
egy would be afatinib, the irreversible EGFR/HER2
inhibitor.
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